lucitanib

VEGFR/FGFR dual kinase inhibitor E-3810

A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C95726" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95726" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000694590

VEGFR/FGFR dual kinase inhibitor E-3810

E-3810

1-naphthalenecarboxamide, 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxy-4-quinolinyl)oxy)-n-methyl-

AL3810

1058137-23-7

C4733244

C3887576

C3887574

C0286475

2011-01-28

2014-02-13

A novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. Lucitanib inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C95726" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95726" NCI Thesaurus)

C95726

CDR0000694590

Drug/agent

lucitanib

T109

T121